With the rising popularity of glucagon-like peptide-1 agents for treating obesity, many bariatric surgery programs across the ...

Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide ...

Expanding access to obesity medications such as glucagon-like peptide 1 (GLP-1) receptor agonists and dual gastric inhibitory polypeptide and GLP-1 receptor agonists could avert 42,000 deaths annually ...

Researchers found that adolescents treated with a glucagon-like peptide 1 receptor agonist (GLP1R) for obesity experienced ...

The majority of patients may safely take glucagon-like peptide 1 receptor agonists (GLP-1 RAs) before elective surgery and ...

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...

While some GLP-1s are approved for patients age 12 and older, only a few telehealth companies will prescribe them to children.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer ...

Medically reviewed by Lindsay Cook, PharmD Ozempic is the brand name of semaglutide, a glucagon-like peptide-1 (GLP-1) ...

The ‘Ozempic drug,’ semaglutide, has been found to reduce moderately severe pain caused by knee osteoarthritis and improve ...

In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, ...